Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > approval date, coincidental?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(82)
•••
Post by Gbathaton May 07, 2021 10:25am
188 Views
Post# 33151705

approval date, coincidental?

approval date, coincidental?This blood test has Full Accreditation for “Microbiology – SARS CoV-2 Antibody Assay” by the College of Physicians and Surgeons of British Columbia’s Diagnostic Accreditation Program using Sierra SPR-32 for  Accredited BC Neuroimmunology Laboratory effective April 1, 2021.

Hmmm... just one day after the end of PMN's fiscal year

Coincidental, or by design/request?  

Why would they not want to disclose this awesome development?  Something good is brewing, imo, and they are delaying any PR announcement to make sure they are ready to launch, also imo.  It is odd that the info is just out there on the covidimmunitypassports website though. 

I'm holding 220K shares ARFXF going into what I hope will be an exciting month for us.  I plan to hold 150K until PMN310 is through Phase II, which could be a while;D But this COVID test could really make this stock the trade of the year if they get a good chunk of that $1B+ market.  glta 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities